Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

Secondary endpoints included change in BMD at the spine at earlier time points and at the total hip, trochanter, and femoral neck at all time points.

Who Took Part

According to the abstract, 412 women were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Teriparatide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Teriparatide group a baseline to be compared against.

More than one site took part, so the women came from several places.

What Was Measured

Secondary endpoints included change in BMD at the spine at earlier time points and at the total hip, trochanter, and femoral neck at all time points.

Topics PubMed links to this paper include Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Collagen Type I, Diphosphonates and Imidazoles.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide in 412 women.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2011 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Teriparatide compound page, all human trials.